Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05914389
Other study ID # 2023-0296
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 2023
Est. completion date August 2030

Study information

Verified date April 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Li Jun, MD
Phone +86 13777878061
Email 2307016@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.


Description:

The standard treatment for locally advanced colon cancer is surgery followed by adjuvant chemotherapy containing oxaliplatin. The MOSAIC and 16968 studies have shown that approximately 30% of patients experience recurrence and metastasis within 6-7 years after surgery. Neoadjuvant chemotherapy may improve the prognosis of patients with malignant tumors. The significant tumor shrinkage after neoadjuvant therapy indicates a greater likelihood of long-term survival for patients. The OPTICAL and FoxTROT studies have shown that approximately 35% of patients are resistant to oxaliplatin-containing neoadjuvant chemotherapy, with a pCR rate of less than 10% and uncertain survival improvement. In addition, immunotherapy has poor efficacy for microsatellite stable (MSS) patients. Therefore, it is necessary to explore new and effective neoadjuvant treatment modalities for tumor regression. The study will screen for individuals who are sensitive to oxaliplatin-containing regimens through induction chemotherapy. Immunogenic cell death will be enhanced by oxaliplatin-induced immunogenicity and combined with anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies for neoadjuvant therapy. In the context of cancer, the role of the intestinal microbiome in mediating immune activation induced by chemotherapy drugs has been demonstrated. Clostridium butyricum will be introduced as an adjuvant to explore the possibility of further increasing the significant response rate of neoadjuvant therapy. The study will first conduct 2 cycles of Capox induction chemotherapy to screen for patients sensitive to chemotherapy. Patients will be randomized into three cohorts: one chemotherapy standard control cohort (continuing Capox chemotherapy for 2 cycles) and two enhancement design cohorts (Capox chemotherapy + Anti-PD-L1 monoclonal antibody for 2 cycles/Capox chemotherapy + Anti-PD-L1 monoclonal antibody + Clostridium butyricum for 2 cycles), followed by CME surgery. The study's primary endpoint is the proportion of Tumor regression grade(TRG)0/1 in the pathological specimens of surgically resected tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date August 2030
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age =18 years old and =75 years old. - Pathologically diagnosed MSS or pMMR-type colon adenocarcinoma. - The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination. - Enhanced CT stage T3/4 or T1-4N+ without multiple primary tumors or distant metastasis. - Life expectancy is expected to be more than 1 year. - First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications. - Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent. Exclusion Criteria: - Refused to participate in this study. - Multifocal colorectal cancer. - History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers. - Cannot tolerate chemotherapy, such as but not limited to bone marrow suppression. - Acute exacerbation of important organ diseases (such as but not limited to COPD, coronary heart disease, and renal insufficiency) and/or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), ASA score > 3 points. - Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol. - Tumor obstruction or high risk of obstruction, bleeding, and/or perforation. - Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy. - Pregnancy or lactation. - Unable to undergo enhanced CT examination or having comorbidities requiring the use of glucocorticoid therapy. - Continuous use of glucocorticoids for more than 3 days within 1 month prior to signing the informed consent form. - CT or MRI in the mid-sagittal plane shows that the lower border of the tumor is below the line connecting the sacrococcygeal promontory and the upper border of the pubic symphysis. - Other situations in which the researcher deems unsuitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxaliplatin
Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Capecitabine
Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Anti-PD-L1 Monoclonal Antibody
The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
Clostridium butyricum
Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
Procedure:
Colectomy
The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.

Locations

Country Name City State
China Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary TRG0/1 The sum of tumor regression grades TRG0(disappearance of tumor) and TRG1(scattered residual tumor)(AJCC standard). 1 day of postoperative pathological examination.
Secondary AE the rate of adverse event(AE). Adverse events (NCI CTC AE 5.0) that occurred from the first day of induction chemotherapy to one day before the surgery date(up to half a year).
Secondary Surgical Complication the rate of surgical complication during or after operation. From the day of surgery to 30 days after the operation, including intraoperative and postoperative complications.
Secondary DFS 3-year Disease-free survival. From date of the patient signs the informed consent form until the date of earliest occurrence of the patient's tumor recurrence or death,whichever came first, assessed up to 36 months.
Secondary OS 5-year Overall survival. From the date of the patient signs the informed consent form until the date of the patient's death, assessed up to 60 months.
Secondary Concentration of FLT3L Fms Related Receptor Tyrosine Kinase 3 Ligand is a marker of immunogenic cell death. blood tests for FLT3LG at initial diagnosis, after induction chemotherapy, before and 3 months after surgery.
Secondary Concentration of cytokines Blood density measurement of immunoreaction associated cytokines. Blood tests of cytokines such as IFN-? are conducted using techniques such as immunofluorescence and ELISA at initial diagnosis, after induction chemotherapy, before and 3 months after surgery.
Secondary T lymphocyte Cells with cellular immune function. The types and counts of T cells are analyzed using flow cytometry at initial diagnosis, after induction chemotherapy, before surgery, and 3 months after surgery.
Secondary Molecular pathological analysis of tumor tissue. Whole exome sequencing and Nanostring to analyze changes in the tumor microenvironment immune status. Nanostring and Whole exome gene sequencing is performed on tumor specimens to analyze the changes in immune cell types, counts, and other immune status-related factors in the tumor microenvironment before and after treatment (up to half a year).
Secondary Minimal Residual Disease (MRD) Minimal Residual Disease which is a potential source of tumor recurrence and distant metastasis. Collect plasma after surgery for MRD detection (up to half a year).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Terminated NCT04555135 - A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) Assistance Software In Detecting Colon Polyps During Standard Colonoscopy Procedures N/A
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05279612 - Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer
Active, not recruiting NCT04369053 - Prevention of Colorectal Cancer Through Multiomics Blood Testing
Recruiting NCT05411783 - Low Tie Versus High Tie of the Inferior Mesenteric Vein During Colorectal Cancer Surgery: A Randomized Clinical Trial N/A
Recruiting NCT05345613 - Tranexamic Acid During Colonic Endoscopic Resection Procedures Phase 4
Recruiting NCT03803891 - Endoscopic Full-Thickness Resection In Colon
Completed NCT04799080 - Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
Recruiting NCT05034692 - Application of Overlap Method to Digestive Tract Reconstruction of Totally Laparoscopic Left Colectomy N/A
Recruiting NCT04920149 - Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Phase 2
Not yet recruiting NCT00295035 - Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer Phase 3
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT03198338 - Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit N/A
Completed NCT05497726 - Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW N/A
Completed NCT03730441 - Correlation Between ADR of Screening and All Colonoscopies
Completed NCT03723720 - Calculating of Correlations Between ADR, PDR, MAP
Recruiting NCT05446558 - Long-term Results in Intracorporeal Versus Extracorporeal Anastomosis in Laparoscopic Right Colectomy N/A
Recruiting NCT03458689 - Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Patients Undergoing Left Hemicolectomy N/A
Completed NCT03719573 - Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer N/A